View Older Stories View More Recent Stories
-
Pharma Stocks on Watch as Draft Obamacare Reform Bill Makes No Mention of Drug Prices - Evercore's Raffatt
-
Evercore ISI Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
Impax Laboratories (IPXL) Generic EpiPen Shows 'Meaningful Gains' Versus Mylan's EpiPen - Evercore ISI Raffat
-
Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
-
Valeant Pharma (VRX): 'Finally Some Good News' - Evecore ISI's Raffat
-
Allergan (AGN) on Watch After Raising Drug Prices
-
Allergan (AGN) Sees Sneaky Gains Into Year-End After Disastrous 2016
-
Allergan (AGN) Has an Important Catalyst Forthcoming that is Flying Under the Radar - Evercore ISI's Raffat
-
Medicines Co. (MDCO) Recovers; Evercore ISI's Raffat Says Data 'Looks Very Consistent and Durable'
-
Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's Raffat
-
Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI Raffat
-
Allergan CEO takes blame for big miss on quarterly earnings
-
Evercore ISI named # 3 in U.S. Equity Research by Institutional Investor's All-America Equity Research Survey
-
Valeant Pharma (VRX), Other Pharma Stocks Weaker as Clinton Op-Ed Discusses Measures on Drug Prices
-
Allergan (AGN) Namenda Concerns 'Not a Big Deal' - Evecore ISI's Raffat
-
Evercore ISI Raffat Highlights New Development on Teva Pharma (TEVA) from Copaxone Hearing
-
Mylan CEO to testify before House panel over EpiPen pricing
-
1997 CMS Letter to Mylan (MYL) Shows Evidence of EpiPen Medicaid Rebate - Evecore ISI's Raffat
-
Evercore ISI Starts Theravance Biopharma (TBPH) at Buy
-
Why All the Outcry About EpiPen Prices Now? It's Back to School Time
-
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore
-
Senate Hearing on Mylan (MYL) EpiPen Pricing Likely in the Works - Evercore ISI
-
Epipen Pricing Debate Has Mylan (MYL) Investors on Edge
-
All Eyes on Valeant Pharma (VRX) EBITDA, Which is Expected to be Lowered - Evecore ISI's Raffat
-
Medicines Co. (MDCO) on Watch as Pfizer Backs Off Competitive PCSK9
-
Medicines Co. (MDCO): Market Under-Estimating What Angiomax Decision Means - Evercore ISI
-
EU Divestiture Not Required Before Allergan (AGN)/Teva Pharma (TEVA) Close - Evecore ISI's Raffat
-
Medicines Co. (MDCO) Gains Amid Positive Analyst Call
-
Evecore ISI's Raffat Not Worried About New Alkermes plc (ALKS) IPR Challenge
-
Valeant Pharma (VRX) EBITDA Guidance Just Above Maintenance Covenants - Evercore ISI's Raffat
-
Mylan NV (MYL): Another Epipen Competitor Delayed, Possible Catalyst for EPS Increases - Evercore ISI
-
Alkermes (ALKS) Data Shines Positive Light on Phase 3 Trial Miss - Evecore ISI
-
Medicines Co. (MDCO) Gains as En Banc Hearing Said to Have 'Went Well'
-
Debt-laden Valeant faces tough choices in asset sales
-
Debt-laden Valeant faces tough choices in asset sales
-
Evercore ISI Defends Allergan (AGN) Following Negative Report
-
Synthon's Generic Copaxone 20mg Approved in Europe Today - Analyst (TEVA)
-
New U.S. inversion rules threaten Pfizer-Allergan deal
-
FDA Puts Out Guidance on Biosimilar Labeling
-
Apricus Bio's (APRI) ALD403 Data is Positive, But May Not Compare to Prior Teva Data - Evercore
-
Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat
-
The Single Most Important Catalyst for Valeant Pharma (VRX) Near-Term...
-
Drugmaker Valeant faces debt default risk; shares plunge 50 percent
-
Valeant shares slide on news of probe by U.S. SEC
-
Valeant CEO Pearson to return effective immediately, results delayed
-
Valeant shares jump 9 percent after announcement of plans to restate
-
Valeant Pharma (VRX) TRx Continues Gains in Week 3 of Walgreens Deal - Evecore ISI
-
Valeant Pharma (VRX) IMS Script Data Remains Strong in Week 2 Post-Walgreens - Evercore ISI
-
'No Blatant Lies' Seen from Valeant (VRX) CEO/CFO Exchange and Philidor Scripts Were Not Just Smoke and Mirrors - Evercore ISI
-
Evercore ISI Follows Up on Valeant Pharma (VRX) Response to Questions

